Pediatric ulcerative colitis: Current treatment approaches including role of infliximab

Gia M. Bradley, Maria Oliva-Hemker

Research output: Contribution to journalReview articlepeer-review

16 Scopus citations


Ulcerative colitis is a chronic inflammatory bowel disease that can lead to derangements in the growth, nutritional status, and psychosocial development of affected children. There are several medical options for the induction and maintenance of disease remission, but the benefits of these medications need to be carefully weighed against the risks, especially in the pediatric population. As the etiology of the disease has become increasingly understood, newer therapeutic alternatives have arisen in the form of biologic therapies, which are monoclonal antibodies targeted to a specific protein or receptor. This review will discuss the classical treatments for children with ulcerative colitis, including 5-aminosalicylates, corticosteroids, thiopurine immunomodulators, and calcineurin inhibitors, with a particular focus on the newer class of anti-tumor necrosis factor-α agents.

Original languageEnglish (US)
Pages (from-to)125-134
Number of pages10
JournalBiologics: Targets and Therapy
StatePublished - Oct 2 2012


  • 5-aminosalicylates
  • Anti-tumor necrosis factor-αAgents
  • Corticosteroids
  • Cyclosporine
  • Inflammatory bowel disease
  • Thiopurine immunomodulators

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Oncology
  • Gastroenterology
  • Pharmacology (medical)


Dive into the research topics of 'Pediatric ulcerative colitis: Current treatment approaches including role of infliximab'. Together they form a unique fingerprint.

Cite this